科伦药业(002422) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 reached ¥5,601,800,088, representing a 24.98% increase compared to ¥4,482,032,531 in the same period last year[3] - Net profit attributable to shareholders was ¥810,322,186, a significant increase of 178.10% from ¥291,374,063 in the previous year[3] - Basic earnings per share rose to ¥0.56, up 180.00% from ¥0.20 in the same quarter last year[3] - Total comprehensive income for Q1 2023 was CNY 907,228,688, significantly higher than CNY 251,103,116 in Q1 2022[21] - Operating profit for the quarter was CNY 1,123,086,114, compared to CNY 333,467,173 in the previous year, marking a substantial increase[20] Cash Flow - The net cash flow from operating activities surged to ¥1,511,963,345, marking a dramatic increase of 3,488.95% compared to ¥42,128,261 in Q1 2022[3] - Total cash inflow from operating activities reached ¥6,988,169,723, compared to ¥4,994,414,494 in the same period last year, indicating a year-over-year growth of approximately 39.9%[23] - Cash outflow for operating activities was ¥5,476,206,378, up from ¥4,952,286,233, representing an increase of about 10.6%[23] - The company reported cash inflow from investment activities of ¥845,957,925, significantly higher than ¥379,149,814 in the previous year, marking a growth of approximately 123.5%[23] - The net cash flow from investment activities was negative at -¥474,721,399, worsening from -¥133,544,768 year-over-year[23] - Cash inflow from financing activities totaled ¥2,598,445,100, down from ¥4,922,444,738, indicating a decline of about 47.3%[23] - The net cash flow from financing activities was ¥166,550,914, a sharp decrease from ¥2,420,954,041 in the previous year[23] - The ending balance of cash and cash equivalents was ¥5,874,530,504, an increase from ¥5,122,279,640 year-over-year[23] - The company’s cash and cash equivalents increased by ¥1,202,980,668 during the quarter, compared to an increase of ¥2,322,270,851 in the same period last year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥36,105,504,505, reflecting a 5.82% increase from ¥34,118,379,816 at the end of the previous year[3] - The total liabilities amounted to CNY 17,510,071,026, a slight increase from CNY 17,230,414,051 in the previous year[19] - The company’s total equity rose to CNY 18,595,433,479, compared to CNY 16,887,965,765 in Q1 2022, reflecting a growth of 10%[19] - The company reported a decrease in sales expenses to CNY 1,159,695,620, down from CNY 1,206,013,558 in Q1 2022[20] - The company’s total liabilities decreased by 46.30% for non-current liabilities due within one year, amounting to ¥1,089,488,231[6] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 35,017, with no preferred shareholders having restored voting rights[9] - Major shareholder Liu Gexin holds 25.77% of shares, totaling 379,128,280 shares, with 284,346,210 shares subject to trading restrictions[11] - Shareholder Hong Kong Central Clearing Limited holds 6.50% of shares, totaling 95,622,508 shares, all of which are unrestricted[12] - The top ten shareholders collectively hold a significant portion of the company's shares, indicating strong institutional interest[11] - The total number of shares held by the top ten unrestricted shareholders is 339,000,000 shares[12] Investment Management - The company has entrusted financial management with a total amount of 99,500,000 RMB, including 94,500,000 RMB in bank wealth management products and 5,000,000 RMB in large-denomination certificates of deposit[14] - The expected annualized return rate for structured deposits is 3.10% and 3.20%, with actual returns of 12.74 and 13.59 respectively[15] - The company has a total of 62,000,000 RMB in unexpired balances from entrusted financial management[14] - The company has no overdue amounts from entrusted financial management, indicating effective financial oversight[14] - The company is actively managing its investments through structured deposits, reflecting a strategic approach to capital allocation[15] Structured Deposits - Total structured deposits amounted to CNY 99,500 million, with a total interest of CNY 488.89 million for the reporting period[16] - The highest interest rate for structured deposits was 3.43%, offered by Chengdu Bank Shuangliu Gongxing Branch[16] - The total interest earned from structured deposits was CNY 313.58 million, with a significant portion from deposits maturing in the next few months[16] - The average interest rate across all structured deposits was approximately 3.20%[16] - The largest single structured deposit recorded was CNY 12,500 million, with an interest rate of 3.00%[16] - The total interest from structured deposits at Chengdu Bank Shuangliu Gongxing Branch reached CNY 89.56 million[16] - The structured deposits from the Transportation Bank Chengdu Xindu Branch totaled CNY 20,000 million, with an average interest rate of 3.05%[16] - The report indicates a focus on maintaining capital protection while offering floating returns on structured deposits[16] - The company plans to continue expanding its structured deposit offerings to enhance liquidity management[16] - The financial strategy includes leveraging high-interest structured deposits to optimize overall asset returns[16] Research and Development - R&D expenses increased to CNY 491,663,537, representing a 17.8% rise from CNY 417,052,131 in Q1 2022[20] - Kelun's innovative drug TROP2-ADC (SKB264) has been included in the list of "breakthrough therapy varieties" by the National Medical Products Administration, highlighting its potential in treating advanced NSCLC[17] Other Developments - The company received an upfront payment of USD 17.5 million from Merck for seven ongoing ADC projects, indicating progress in its collaboration with the pharmaceutical giant[17] - The company’s subsidiary, Kelun Botai, has submitted an application for an overseas IPO (H shares) to the China Securities Regulatory Commission, which has been accepted[17] - The company participated in the eighth batch of national centralized drug procurement, with seven products expected to win bids, indicating a strategic move to enhance market presence[17]